BR0009465A - Formulação farmacêutica na forma de uma cápsula par administração oral, uso de undecanoato de testosterona, e, método de tratamento compreendendo a administração de undecanoato de testosterona a um homem em necessidade de suplementação de andrógeno - Google Patents

Formulação farmacêutica na forma de uma cápsula par administração oral, uso de undecanoato de testosterona, e, método de tratamento compreendendo a administração de undecanoato de testosterona a um homem em necessidade de suplementação de andrógeno

Info

Publication number
BR0009465A
BR0009465A BR0009465-0A BR0009465A BR0009465A BR 0009465 A BR0009465 A BR 0009465A BR 0009465 A BR0009465 A BR 0009465A BR 0009465 A BR0009465 A BR 0009465A
Authority
BR
Brazil
Prior art keywords
testosterone undecanoate
administration
oral administration
capsule
man
Prior art date
Application number
BR0009465-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Henrik De Nijs
Susan Chandler
Elizabeth Anne Perry
Josephine Joan Chri Ferdinando
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR0009465A publication Critical patent/BR0009465A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
BR0009465-0A 1999-04-01 2000-03-27 Formulação farmacêutica na forma de uma cápsula par administração oral, uso de undecanoato de testosterona, e, método de tratamento compreendendo a administração de undecanoato de testosterona a um homem em necessidade de suplementação de andrógeno BR0009465A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99302581 1999-04-01
PCT/EP2000/002677 WO2000059512A1 (en) 1999-04-01 2000-03-27 Formulation comprising testosteron undecanoate and castor oil

Publications (1)

Publication Number Publication Date
BR0009465A true BR0009465A (pt) 2002-01-08

Family

ID=8241306

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009465-0A BR0009465A (pt) 1999-04-01 2000-03-27 Formulação farmacêutica na forma de uma cápsula par administração oral, uso de undecanoato de testosterona, e, método de tratamento compreendendo a administração de undecanoato de testosterona a um homem em necessidade de suplementação de andrógeno

Country Status (26)

Country Link
EP (1) EP1189620B1 (enExample)
JP (1) JP2002541111A (enExample)
KR (1) KR100666016B1 (enExample)
CN (1) CN1155385C (enExample)
AT (1) ATE269708T1 (enExample)
AU (1) AU768537B2 (enExample)
BR (1) BR0009465A (enExample)
CA (1) CA2366856C (enExample)
CZ (1) CZ298573B6 (enExample)
DE (1) DE60011771T2 (enExample)
DK (1) DK1189620T3 (enExample)
ES (1) ES2222199T3 (enExample)
HU (1) HU229455B1 (enExample)
ID (1) ID30481A (enExample)
IL (2) IL145524A0 (enExample)
MX (1) MXPA01009919A (enExample)
NO (1) NO329420B1 (enExample)
NZ (1) NZ514290A (enExample)
PL (1) PL195163B1 (enExample)
PT (1) PT1189620E (enExample)
RU (1) RU2246296C2 (enExample)
SK (1) SK286071B6 (enExample)
TR (1) TR200102769T2 (enExample)
TW (1) TWI280124B (enExample)
WO (1) WO2000059512A1 (enExample)
ZA (1) ZA200107781B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
JO2505B1 (en) 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
ES2258694T3 (es) * 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
US8241664B2 (en) 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
DK2068825T3 (da) 2006-10-04 2011-05-16 M & P Patent Ag Kontrolleret frisætningstilførselssystem til nasal påføring af neurotransmittere
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2011129812A1 (en) * 2010-04-12 2011-10-20 Clarus Therapeutics, Inc. Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
AU2012209184B2 (en) * 2011-01-26 2017-06-15 Allergan, Inc. Androgen composition for treating an opthalmic condition
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
WO2015193224A1 (en) 2014-06-17 2015-12-23 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
KR102397569B1 (ko) * 2014-06-19 2022-05-12 솔루랄 파마 에이피에스 친유성 화합물의 고형 경구 투여 형태
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
CN106999558A (zh) * 2014-08-29 2017-08-01 来普卡公司 (17‑β)‑3‑氧雄甾‑4‑烯‑17‑基十一酸酯组合物及其制备方法和用途
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
EP3824296B1 (en) 2018-07-20 2026-04-01 Lipocine Inc. Oral pharmaceutical composition comprising testosterone tridecanoate and/or testosterone dodecanoate for treating liver diseases
US11564933B2 (en) 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1102095A (zh) * 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9415810D0 (en) * 1994-08-04 1994-09-28 Jerrow Mohammad A Z Composition
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) * 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet

Also Published As

Publication number Publication date
NZ514290A (en) 2003-08-29
KR100666016B1 (ko) 2007-01-10
NO329420B1 (no) 2010-10-18
PL195163B1 (pl) 2007-08-31
PT1189620E (pt) 2004-10-29
DK1189620T3 (da) 2004-08-16
HU229455B1 (en) 2013-12-30
CN1346274A (zh) 2002-04-24
SK13722001A3 (sk) 2002-02-05
JP2002541111A (ja) 2002-12-03
ES2222199T3 (es) 2005-02-01
IL145524A (en) 2006-12-31
NO20014718L (no) 2001-09-28
HK1043544A1 (en) 2002-09-20
NO20014718D0 (no) 2001-09-28
TR200102769T2 (tr) 2002-05-21
CA2366856A1 (en) 2000-10-12
IL145524A0 (en) 2002-06-30
EP1189620B1 (en) 2004-06-23
AU4111100A (en) 2000-10-23
CZ20013507A3 (cs) 2002-03-13
HUP0200453A3 (en) 2003-06-30
ID30481A (id) 2001-12-13
RU2246296C2 (ru) 2005-02-20
CN1155385C (zh) 2004-06-30
PL351259A1 (en) 2003-04-07
HUP0200453A2 (hu) 2002-07-29
ZA200107781B (en) 2002-12-20
CA2366856C (en) 2006-05-16
TWI280124B (en) 2007-05-01
DE60011771T2 (de) 2004-11-04
KR20010108435A (ko) 2001-12-07
CZ298573B6 (cs) 2007-11-14
MXPA01009919A (es) 2002-04-24
EP1189620A1 (en) 2002-03-27
SK286071B6 (sk) 2008-02-05
DE60011771D1 (de) 2004-07-29
AU768537B2 (en) 2003-12-18
ATE269708T1 (de) 2004-07-15
WO2000059512A1 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
ID30481A (id) Formulasi yang terdiri dari testosteron undekanoat dan minyak kastor
RU2001129362A (ru) Композиция, включающая ундеканоат тестостерона и касторовое масло
ES2602450T3 (es) Composición farmacéutica para uso dérmico para el tratamiento de la psoriasis que comprende calcipotril y betametasona
DK1173153T3 (da) Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
PA8542701A1 (es) Composición parenteral reconstituible
JP7280870B2 (ja) 皮膚障害の処置
MXPA03005672A (es) Metodo y composicion para el tratamiento de la neuropatia diabetica.
ES2238985T3 (es) Composiciones para el tratamiento de enfermedades de la piel.
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
NZ503551A (en) PDE4 inhibitors for the treatment of inflammatory skin diseases
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
MX2009002311A (es) Composiciones farmaceuticas para tratamiento de infecciones fungales.
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
JP2010529175A (ja) マラセチア属酵母に対して抗真菌活性を有するテルペン
UY26459A1 (es) 3,4-dihidroquinazolinas 5,6-disustituidas
US8263567B2 (en) Treatment of hyperproliferative conditions of body surfaces
AR023235A1 (es) Formulaciones de androgenos
WO1996033714A1 (en) Treatment of actinic keratosis, displastic nevi and other proliferative skin disorders with topical clotrimazole
AR002716A1 (es) Uso farmacologico de ciertos derivados de cistina para la preparacion de un medicamento
CA2942345A1 (en) Low-dose estradiol cream
TH33003B (th) สูตรตำรับแอนโดรเจน
TH60756A (th) สูตรตำรับแอนโดรเจน

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.